Activity – Page 2

Gilead’s $35M Herpes Deal with Assembly Biosciences and Recent FDA Approvals

1 month ago talkbio0Tagged ABI-5366, Assembly (construction), Boehringer, Gilead, Herpes NOS, Herpes Simplex Infections, Roche (company), United States Food and Drug Administration

Gilead; Assembly Biosciences; herpes; HSV; ABI-1179; ABI-5366; FDA; Boehringer; Roche

Jim Lang Appointed to the Board of Directors of Halozyme Therapeutics

1 month ago talkbio0Tagged Appointments, Bench International, Biological Factors, BioVie, board of directors, Corporate governance, drug delivery platform, election, Halozyme Therapeutics, Jim Lang

Jim Lang; Halozyme Therapeutics; Board of Directors; appointment; election; Bench International; biopharmaceutical; drug delivery platform; corporate governance; OptimizeRx; BioVie

Ankyra Therapeutics Appoints Sailaja Battula, PhD as Chief Scientific Officer

1 month ago talkbio0Tagged Ankyra Therapeutics, Appointments, Biotechnology, CSO, immuno-oncology, Sailaja Battula

Ankyra Therapeutics; Sailaja Battula; CSO appointment; immuno-oncology; biotechnology

The Endpoints 100: Biotech CEOs are feeling more upbeat about the road ahead

2 months ago talkbio0Tagged Attitude, biopharma executives, CEOs, dealmaking, E100 survey, Endpoints, Industry, IPO, Market, Recovery - action, reorganization, Sentiment, Trump administration, United States Food and Drug Administration, Window (physical object)

Endpoints 100; E100 survey; biotech CEOs; biopharma executives; industry sentiment; market recovery; dealmaking; IPO window; Trump administration; FDA reorganization; tariffs; 2025 outlook

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

2 months ago talkbio0Tagged ARIA risk, Binding action, Biological Markers, clinical outcomes, Dental Plaque, oligomer selectivity, Phase 1b Trial, PMN310, PRECISE-AD trial, ProMIS Neurosciences, Toxic Oligomers, vascular deposit binding

ProMIS Neurosciences; PMN310; toxic oligomers; ARIA risk; PRECISE-AD trial; peer-reviewed publication; oligomer selectivity; plaque binding; vascular deposit binding; phase 1b trial; biomarkers; clinical outcomes

SanegeneBio raises over $110M Series B after Lilly RNAi deal

2 months ago talkbio0Tagged clinical-stage assets, eli lilly, extrahepatic RNAi, Fund Raising, Lilly collaboration, liver-targeted RNAi, Metabolic Diseases, RNA, RNA Interference, SanegeneBio, Series B financing

SanegeneBio; Series B financing; $110 million; Eli Lilly; RNA interference; RNAi therapeutics; metabolic diseases; Lilly collaboration; clinical-stage assets; liver-targeted RNAi; extrahepatic RNAi; biotech fundraising 2025

Bruker Adds Diagnostics Leader Jack Phillips to Board of Directors Effective January 2026

2 months ago talkbio0Tagged Accelerate Diagnostics, Appointments, board of directors, Bruker Corporation, Corporate governance, diagnostics industry, Jack Phillips, Roche Diagnostics North America, Ventana Medical Systems * *

Bruker Corporation; Jack Phillips; Board of Directors; appointment; January 1 2026; diagnostics industry; corporate governance; Accelerate Diagnostics; Roche Diagnostics North America; Ventana Medical Systems

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Data in Leptomeningeal Metastases at SABCS 2025

2 months ago talkbio0Tagged central nervous system cancers, Dosage, Escalation, Metastatic Malignant Neoplasm to the Leptomeninges, Phase 1 (qualifier value), Plus Therapeutics, poster spotlight, ReSPECT-LM, REYOBIQ, SABCS, San Antonio Breast Cancer Symposium, Therapeutic radiology procedure

Plus Therapeutics; ReSPECT-LM; Phase 1; dose escalation; REYOBIQ; leptomeningeal metastases; San Antonio Breast Cancer Symposium; SABCS 2025; poster spotlight; central nervous system cancers; radiotherapeutics

Vera Therapeutics Appoints James R. Meyers to Its Board of Directors

2 months ago talkbio0Tagged Appointments, Atacicept, Autoimmune Diseases, Biological Factors, biotech executive, board of directors, Gilead Sciences, IGA Glomerulonephritis, IntraBio Ltd., James, Vera Therapeutics

Vera Therapeutics; James R. Meyers; Board of Directors; appointment; biotech executive; IgA nephropathy; atacicept; autoimmune diseases; Gilead Sciences; IntraBio Ltd; biopharmaceutical

Zentek Appoints Mohammed Jiwan as CEO

2 months ago talkbio0Tagged Appointments, CEO, commercialization, Graphene, Jiwan, Mohammed, Nanostructured Materials, Technology, ZenGUARD, Zentek

Zentek; Mohammed Jiwan; CEO appointment; ZenGUARD; nanomaterials; graphene; technology; commercialization